Roche: Chugai launches new hemophiia A drug in Taiwan
(CercleFinance.com) - Chugai, the Japanese subsidiary of Roche, said on Friday that it has launched Hemlibra, its new drug created for routine prophylaxis of hemophilia A with inhibitors, in Taiwan.
Hemlibra - a monoclonal antibody which was developed using Chugai's proprietary antibody engineering technology - is used by over 4,000 people with hemophilia A worldwide.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Hemlibra - a monoclonal antibody which was developed using Chugai's proprietary antibody engineering technology - is used by over 4,000 people with hemophilia A worldwide.
Copyright (c) 2019 CercleFinance.com. All rights reserved.